India, June 11 -- CytoDyn Inc. (CYDY), a clinical-stage oncology company, on Thursday announced dosing of the first patient in the Phase 2a SALIENT-AD trial for Leronlimab in treating Alzheimer's disease.
Shares fell over 5% on Thursday.
Alzheimer's disease is a complex neurodegenerative condition characterized amyloid-beta plaques in the brain, tau tangles, chronic neuroinflammation, microglial activation, and disruption of the blood-brain barrier. Research suggests that CCR5, a chemokine receptor expressed on immune cells, may influence autophagy, vascular health, and blood-brain barrier stability.
Leronlimab is a first-in-class humanized monoclonal antibody targeting the CCR receptor. By blocking CCR5, the drug may promote neuronal re...